title: The dosage of infliximab in the treatment of ankylosing spondylitis: dollars and sense.
abstract: While it seems clear that anti-TNF treatments do improve the clinical condition of patients with ankylosing spondylitis, there is some evidence that doses much smaller than those formally studied in controlled trials may also be very effective, and we would recommend that this aspect be pursued given the overall costs involved.
authors.affiliation: Rheumatic Disease Unit, University of Alberta, Edmonton, Canada.
authors.forename: A S
authors.initials: AS
authors.lastname: Russell
authors.forename: J H
authors.initials: JH
authors.lastname: Orozco
authors.forename: W P
authors.initials: WP
authors.lastname: Maksymowych
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000191:economics; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D006801:Humans; D000069285:Infliximab; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab